Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Human Metabolome TechnologiesTSE:6090 -3.10%62 Interest Coverage is 357.24 as of Mar. 2026, which is 284% above its 10-year median of 93.15. GuruFocus rates TSE:6090 with a GF Score™ of 62/100 and a GF Value™ of 円693.69 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 94 Medical Diagnostics & Research companies, Human Metabolome Technologies ranks better than 85.11% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Human Metabolome Technologies's
Operating Income
for the
three
months ended in Mar. 2026 was 円162 Mil. Human Metabolome Technologies's Interest Expense for the
three
months ended in Mar. 2026 was 円-0 Mil.
Human Metabolome Technologies's interest coverage for the quarter that ended in Mar. 2026 was 357.24.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Human Metabolome Technologies Inc has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Human Metabolome Technologies's Interest Coverage or its related term are showing as below:
TSE:6090'
s Interest Coverage Range Over the Past 10 Years
Min: 25.6 Med: 93.15 Max: 105.86
Current: 105.86
TSE:6090's Interest Coverage is ranked better than 85.11% of 94
companies
in the Medical Diagnostics & Research industry
Industry Median: 10.245
vs TSE:6090: 105.86
Human Metabolome Technologies (TSE:6090) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Human Metabolome Technologies Interest Coverage Related Terms
Human Metabolome Technologies Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Human Metabolome Technologies Interest Coverage Chart
TSE:6090 vs TMO, DHR, IDXX: Interest Coverage Comparison
For the Diagnostics & Research subindustry, Human Metabolome Technologies's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Human Metabolome Technologies Interest Coverage vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Human Metabolome Technologies's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Human Metabolome Technologies's Interest Coverage falls into.
Human Metabolome Technologies Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Human Metabolome Technologies (TSE:6090) has a Interest Coverage of 357.24 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Human Metabolome Technologies and its competitors. This is 284% above median its historical median of 93.15. Over the past decade, Human Metabolome Technologies' Interest Coverage has ranged from 25.60 to 105.86. According to the industry distribution chart, Human Metabolome Technologies ranks #14 out of 94 companies in the Medical Diagnostics & Research industry, placing it in the top 14.9%.
Is Human Metabolome Technologies' Interest Coverage too high?
Human Metabolome Technologies' current Interest Coverage of 357.24 is 284% above median its 10-year median of 93.15. Over the past 10 years, this metric has ranged from a low of 25.60 to a high of 105.86. The Medical Diagnostics & Research industry median Interest Coverage is 10.25. Human Metabolome Technologies' value of 357.24 is 3387% above this industry median. Based on the distribution chart, Human Metabolome Technologies ranks #14 out of 94 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Human Metabolome Technologies has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Human Metabolome Technologies' Interest Coverage compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Human Metabolome Technologies ranks #14 out of 94 companies for Interest Coverage. This places Human Metabolome Technologies in the top 15% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 10.25. Human Metabolome Technologies' value of 357.24 is 3387% above this benchmark. Historically, Human Metabolome Technologies' own Interest Coverage has ranged from 25.60 to 105.86 over the past decade. While the company's 10-year median is 93.15 vs. the industry median of 10.25, Human Metabolome Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Diagnostics & Research company?
The median Interest Coverage among Medical Diagnostics & Research companies is 10.25, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Human Metabolome Technologies's current Interest Coverage of 357.24 is 3387% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Human Metabolome Technologies and its competitors. For the Medical Diagnostics & Research industry, the median Interest Coverage is 10.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Human Metabolome Technologies's current Interest Coverage is 357.24, which is 284% above median its own 10-year median of 93.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Human Metabolome Technologies stock overvalued right now?
Based on GuruFocus' analysis, Human Metabolome Technologies (TSE:6090) is currently considered Modestly Undervalued. The stock's GF Value™ is 円693.69, compared to a current price of 円625.00 — trading 9.9% below its estimated fair value. The current Interest Coverage is 357.24, which is 284% above median its 10-year median of 93.15 and 3387% above the Medical Diagnostics & Research industry median of 10.25. Human Metabolome Technologies' overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Human Metabolome Technologies (TSE:6090), the current Interest Coverage is 357.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Human Metabolome Technologies (TSE:6090) Overvalued in 2026?
Based on GuruFocus' analysis, Human Metabolome Technologies stock appears to be undervalued.
The current stock price of 円625.00 is trading 9.9% below its estimated GF Value™ of 円693.69.
GuruFocus considers Human Metabolome Technologies to be Modestly Undervalued.
Key valuation signals for TSE:6090:
Interest Coverage: 357.24 (284% above median its 10-year median of 93.15)
GF Value™: 円693.69 vs. price of 円625.00 (9.9% below fair value)
Industry Position: 3387% above the Medical Diagnostics & Research median (#14 of 94)
No single metric tells the full story. See the TSE:6090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6090 has been successfully added to your 
